

# United States Patent [19]

Voigt et al.

[11] Patent Number: **5,055,301**

[45] Date of Patent: **Oct. 8, 1991**

[54] **USE OF DEXTRAN SULPHATE FOR THE TREATMENT OF HUMAN PROSTATIC CARCINOMA**

[75] Inventors: **Klaus-Dieter Voigt; Cornelius Knabbe**, both of Hamburg, Fed. Rep. of Germany

[73] Assignee: **Entec Gesellschaft fur Endokrinologische Technologie m.b.h.**, Hamburg, Fed. Rep. of Germany

[21] Appl. No.: **466,617**

[22] Filed: **Jan. 17, 1990**

[30] **Foreign Application Priority Data**

Jan. 20, 1989 [DE] Fed. Rep. of Germany ..... 3902021  
Sep. 20, 1989 [DE] Fed. Rep. of Germany ..... 3935855

[51] Int. Cl.<sup>5</sup> ..... **A61F 13/00; A61K 31/715**

[52] U.S. Cl. .... **424/422; 424/435; 424/436; 514/59; 536/51**

[58] Field of Search ..... **514/59; 424/422, 436, 424/435; 536/51**

[56] **References Cited**

**U.S. PATENT DOCUMENTS**

4,462,987 7/1984 Bonifacio ..... 424/99  
4,780,313 4/1988 Koichiro et al. .... 424/88

**FOREIGN PATENT DOCUMENTS**

1951822 4/1971 Fed. Rep. of Germany .

**OTHER PUBLICATIONS**

Parish et al. Chem. Absts. #108187, 110, 1989.  
Niitani et al., Chem. Absts. #106538q, 82, 1975.  
Zimmermann et al., Chem. Absts. 191381f 98, 1983.  
Roth All About Cancer, Stickley Co. PA, 1985 p. 272.

*Primary Examiner*—Thurman K. Page

*Assistant Examiner*—G. S. Kishore

*Attorney, Agent, or Firm*—Nixon & Vanderhye

[57] **ABSTRACT**

The invention relates to the use of dextran sulphate, optionally in combination with anti-androgen agents, for the treatment of the human prostatic carcinoma. Inhibition of the growth of both androgen-dependent and androgen-independent carcinoma cells is achieved according to the invention. The invention therefore leads to a significant improvement in the possible therapies for human prostatic carcinoma.

**10 Claims, 1 Drawing Sheet**